Identification of Piperazinyl–Difluoro-indene Derivatives Containing Pyridyl Groups as Potent FGFR Inhibitors against FGFR Mutant Tumor: Design, Synthesis, and Biological Evaluation

The fibroblast growth factor receptor (FGFR) signaling pathway plays important roles in cellular processes such as proliferation, differentiation, and migration. In this study, we highlighted the potential of FGFR inhibitors bearing the ( S )-3,3-difluoro-1-(4-methylpiperazin-1-yl)-2,3-dihydro-1 H -indene scaffold containing a crucial 3-pyridyl group for the treatment of FGFR mutant cancers. The representative compound ( S )- 23 , which was identified through comprehensive evaluation, exhibited potent antiproliferative activity with GI 50 in the range of 6.4–10.4 nM against FGFR1 fusion protein-carrying, FGFR2-amplified, and FGFR2 mutant cancer cell lines and good antiproliferative activity against FGFR3 translocation and mutant FGFR4 cancer cell lines, as well as potency assessment against FGFR1–4 kinases. Moreover, compound ( S )- 23 exhibited favorable pharmacokinetic properties, low potential for drug–drug interactions, and very potent antitumor activity in MFE-296 xenograft mouse models with a TGI of 99.1% at the dose of 10 mg/kg. These findings demonstrate that compound ( S )- 23 is a potential therapeutic agent for FGFR mutant tumors.